ERBB2 and breast cancer: SCARNA2 and SNORD94 were significantly upregulated in ER-positive and PR-positive tumors, with SCARNA2 also elevated in HER2-negative cases, suggesting a potential link to hormone-responsive, less aggressive breast cancer subtypes.